TOMA Biosciences is partnering with Real Time Genomics to develop clinical grade analysis tools to process next-generation sequencing data from all types of tumor samples, including tumor DNA circulating in the blood captured via a “liquid biopsy.” Their goal is to eliminate the inconsistent results that currently plague the field, as evidenced by the recent International Cancer Genome Consortium challenges.
Most...